There are 413 resources available
192MO - DESTINY-Breast04 subgroup analyses of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with human epidermal growth factor 2 (HER2)-low, estrogen-receptor (ER) expression immunohistochemistry (IHC) 0-10% metastatic breast cancer (mBC)
Presenter: David Cameron
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Mentor guided discussion
Presenter: Ann Partridge
Session: YO Clinical case discussion
Resources:
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Optimal sequencing in advanced luminal breast cancer
Resources:
Webcast
Case 3: Management of brain metastases in metastatic breast cancer treated with antibody-drug conjugates
Presenter: Eduardo Terán Brage
Session: YO Clinical case discussion
Resources:
Slides
Webcast
Invited Discussant 193MO, 3MO and 192MO
Presenter: Peter A. Fasching
Session: Mini Oral session 2
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Mini Oral session 2
Resources:
Webcast
Mentor guided discussion
Presenter: Evandro de Azambuja
Session: YO Clinical case discussion
Resources:
Slides
Webcast
125MO - Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1+P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: JBCRG20 study (Neo-peaks)
Presenter: Kenichi Inoue
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Q&A and general discussion
Presenter: All Speakers
Session: YO Clinical case discussion
Resources:
Webcast
126MO - HER2DX and pathological complete response in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
Presenter: Adrienne Waks
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast